The objectives of Type 1 Diabetes TrialNet are to delay or prevent the development of T1D in persons at risk and to preserve ?-cell function in those with T1D possessing residual ?-cell function through a highly collaborative network designed to identify individuals at-risk for T1D and to determine their eligibility for- and enrollment into prevention trials and to perform new- onset intervention trials. The USF Diabetes Center has been a very productive Affiliate of the University of Florida and has engaged with the TrialNet Coordinating Center at the University of South Florida to develop novel approaches to increase TrialNet enrollment. The Center is comprised of a committed multi-disciplinary team operating from a state-of-the-art, dedicated clinical and clinical research facility serving greater than 1,400 pediatric and adult patients with T1D. In addition, it has established a regional collaborative network of diabetes care providers with access to thousands of additional existing- and new-onset T1D patients. The PI's experience, including roles as the Indiana University DPT-1 Regional Recruitment Center Director, former Director of the Indiana University TrialNet Clinical Center, and as Chair of the Pathway to Prevention Study, and his successful engagement of T1D stakeholders, have enabled him to make vital contributions to TrialNet and has provided him with valuable insight into TrialNet's current limitations and opportunities for expansion. Funding of the USF TrialNet Clinical Center will greatly enhance his involvement in TrialNet as a voting member of the Steering Committee, potential member of the Clinical Leadership Committee, and collaborator of the Clinical Network Hub. Funding will also permit marked expansion of TrialNet recruitment in the West Central Florida region and gain access to hereto for untapped at-risk populations. The USF Diabetes Center's commitment to pursue clinical studies seeking to ameliorate the development of T1D is evidenced by the marked increase in our TrialNet screening activity, the number of our diabetes clinical trails, and our work with the TrialNet TNCC to develop innovative screening initiatives. Our participation as a TrialNet Clinical Center will permit us to markedly expand our current collaborative efforts on behalf of TrialNet.
This proposal seeks funding for the USF TrialNet Clinical Center to allow USF to build upon its role as a high-performing TrialNet Affiliate, pursuing TrialNet's mission to delay or prevent the development of type 1 diabetes in persons at risk and to preserve the ability to make insulin in those individuals recently diagnosed. Clinical Center funding will allow USF to engage hereto for poorly represented West Florida participants through a network of USF Affiliates and partners. Clinical Center status will also allow the PI, Dr Rodriguez, to more actively contribute to TrialNet as a voting member of the Steering Committee, potential member of the Clinical Leadership Committee, and collaborator of the Clinical Network Hub and Coordinating Center.
|Ismail, Heba M; Xu, Ping; Libman, Ingrid M et al. (2018) The shape of the glucose concentration curve during an oral glucose tolerance test predicts risk for type 1 diabetes. Diabetologia 61:84-92|
|Culina, Slobodan; Lalanne, Ana Ines; Afonso, Georgia et al. (2018) Islet-reactive CD8+ T cell frequencies in the pancreas, but not in blood, distinguish type 1 diabetic patients from healthy donors. Sci Immunol 3:|
|Vecchio, Federica; Lo Buono, Nicola; Stabilini, Angela et al. (2018) Abnormal neutrophil signature in the blood and pancreas of presymptomatic and symptomatic type 1 diabetes. JCI Insight 3:|
|Redondo, Maria J; Steck, Andrea K; Sosenko, Jay et al. (2018) Transcription Factor 7-Like 2 (TCF7L2) Gene Polymorphism and Progression From Single to Multiple Autoantibody Positivity in Individuals at Risk for Type 1 Diabetes. Diabetes Care 41:2480-2486|
|Sanda, Srinath; Type 1 Diabetes TrialNet Study Group (2018) Increasing ICA512 autoantibody titers predict development of abnormal oral glucose tolerance tests. Pediatr Diabetes 19:271-276|
|Yeo, Lorraine; Woodwyk, Alyssa; Sood, Sanjana et al. (2018) Autoreactive T effector memory differentiation mirrors ? cell function in type 1 diabetes. J Clin Invest 128:3460-3474|
|Redondo, Maria J; Geyer, Susan; Steck, Andrea K et al. (2018) A Type 1 Diabetes Genetic Risk Score Predicts Progression of Islet Autoimmunity and Development of Type 1 Diabetes in Individuals at Risk. Diabetes Care 41:1887-1894|
|Greenbaum, Carla J; Speake, Cate; Krischer, Jeffrey et al. (2018) Strength in Numbers: Opportunities for Enhancing the Development of Effective Treatments for Type 1 Diabetes-The TrialNet Experience. Diabetes 67:1216-1225|
|Haller, Michael J; Schatz, Desmond A; Skyler, Jay S et al. (2018) Low-Dose Anti-Thymocyte Globulin (ATG) Preserves ?-Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes. Diabetes Care 41:1917-1925|
|Redondo, Maria J; Geyer, Susan; Steck, Andrea K et al. (2018) TCF7L2 Genetic Variants Contribute to Phenotypic Heterogeneity of Type 1 Diabetes. Diabetes Care 41:311-317|
Showing the most recent 10 out of 45 publications